237 related articles for article (PubMed ID: 36872052)
1. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies
in Non-small Cell Lung Cancer].
Wang Y; Chu T
Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):135-147. PubMed ID: 36872052
[TBL] [Abstract][Full Text] [Related]
2. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
Hu M; Zhong C; Wang J; Chen J; Zhou T
Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
[TBL] [Abstract][Full Text] [Related]
3. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
Bai Q; Wang J; Zhou X
Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
Wang H; Xu Y; Lin J; Huang Y
Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
[TBL] [Abstract][Full Text] [Related]
6. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
7. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
[TBL] [Abstract][Full Text] [Related]
8. Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.
Chen H; Hu S; Patterson AV; Smaill JB; Ding K; Lu X
J Med Chem; 2023 Sep; 66(17):11656-11671. PubMed ID: 37669428
[TBL] [Abstract][Full Text] [Related]
9. Mobocertinib in non-small cell lung cancer.
Liu S; Lowder KE
Drugs Today (Barc); 2022 Nov; 58(11):523-530. PubMed ID: 36422513
[TBL] [Abstract][Full Text] [Related]
10. [Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)].
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):325-337. PubMed ID: 37316442
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
[TBL] [Abstract][Full Text] [Related]
12. Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.
Liu J; Xiang Y; Fang T; Zeng L; Sun A; Lin Y; Lu K
Clin Lung Cancer; 2024 Mar; 25(2):100-108. PubMed ID: 38172024
[TBL] [Abstract][Full Text] [Related]
13. [Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].
Xu M; Luo J; Xu R
Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):151-157. PubMed ID: 36872053
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
[TBL] [Abstract][Full Text] [Related]
15. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
16. [Expert consensus on clinical practice of EGFR exon20 insertion detection in non-small cell lung cancer in China (2024 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):179-188. PubMed ID: 38494765
[TBL] [Abstract][Full Text] [Related]
17. Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.
Viteri S; Minchom A; Bazhenova L; Ou SI; Bauml JM; Shell SA; Schaffer M; Gu J; Rose JB; Curtin JC; Mahadevia P; Girard N
Mol Oncol; 2023 Feb; 17(2):230-237. PubMed ID: 36269676
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Yasuda H; Ichihara E; Sakakibara-Konishi J; Zenke Y; Takeuchi S; Morise M; Hotta K; Sato M; Matsumoto S; Tanimoto A; Matsuzawa R; Kiura K; Takashima Y; Yano S; Koyama J; Fukushima T; Hamamoto J; Terai H; Ikemura S; Takemura R; Goto K; Soejima K
Lung Cancer; 2021 Dec; 162():140-146. PubMed ID: 34808485
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.
Watanabe N; Horio Y; Fujiwara Y
Ann Transl Med; 2022 Dec; 10(23):1283. PubMed ID: 36618815
[TBL] [Abstract][Full Text] [Related]
20.
Yang G; Yang Y; Hu J; Xu H; Zhang S; Wang Y
Front Pharmacol; 2022; 13():984503. PubMed ID: 36425568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
